Axsome Therapeutics, Inc.
AXSM
$210.63
$2.811.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 14.21% | -2.45% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.21% | -2.45% | |||
| Cost of Revenue | -7.88% | 19.43% | |||
| Gross Profit | 16.05% | -3.92% | |||
| SG&A Expenses | 12.51% | 9.27% | |||
| Depreciation & Amortization | 1.08% | -2.18% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.12% | 9.46% | |||
| Operating Income | 18.52% | -74.23% | |||
| Income Before Tax | 20.69% | -129.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.50% | -126.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.50% | -126.00% | |||
| EBIT | 18.52% | -74.23% | |||
| EBITDA | 20.11% | -78.96% | |||
| EPS Basic | 21.42% | -123.47% | |||
| Normalized Basic EPS | 18.59% | -70.01% | |||
| EPS Diluted | 21.42% | -123.47% | |||
| Normalized Diluted EPS | 18.59% | -70.01% | |||
| Average Basic Shares Outstanding | 1.17% | 1.12% | |||
| Average Diluted Shares Outstanding | 1.17% | 1.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||